Literature DB >> 28258457

From Heartburn to Barrett's Esophagus, and Beyond.

Francisco Schlottmann1, Marco G Patti1,2, Nicholas J Shaheen3.   

Abstract

BACKGROUND: Gastroesophageal reflux disease (GERD) affects an estimated 20% of the population in the USA, and its prevalence is increasing worldwide. About 10-15% of patients with GERD will develop Barrett's esophagus (BE). AIMS: The aims of this study were to review the available evidence of the pathophysiology of BE and the role of anti-reflux surgery in the treatment of this disease.
RESULTS: The transformation of the squamous epithelium into columnar epithelium with goblet cells is due to the chronic injury produced by repeated reflux episodes. It involves genetic mutations that in some patients may lead to high-grade dysplasia and cancer. There is no strong evidence that anti-reflux surgery is associated with resolution or improvement in BE, and its indications should be the same as for other GERD patients without BE.
CONCLUSIONS: Patients with BE without dysplasia require endoscopic surveillance, while those with low- or high-grade dysplasia should have consideration of endoscopic eradication therapy followed by surveillance. New endoscopic treatment modalities are being developed, which hold the promise to improve the management of patients with BE.

Entities:  

Mesh:

Year:  2017        PMID: 28258457     DOI: 10.1007/s00268-017-3957-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  64 in total

1.  Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings.

Authors:  A J Cameron; A R Zinsmeister; D J Ballard; J A Carney
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

2.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

3.  The burden of selected digestive diseases in the United States.

Authors:  Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

4.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

5.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

6.  The risk of esophageal adenocarcinoma after antireflux surgery.

Authors:  Jesper Lagergren; Weimin Ye; Pernilla Lagergren; Yunxia Lu
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

Review 7.  Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Abha Goyal Singh; Preet Paul Singh; Mohammad Hassan Murad; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

Review 8.  The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review.

Authors:  Eugene Y Chang; Cynthia D Morris; Ann K Seltman; Robert W O'Rourke; Benjamin K Chan; John G Hunter; Blair A Jobe
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

9.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

Review 10.  Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Sushil Kumar Garg; Preet Paul Singh; Prasad G Iyer; Hashem B El-Serag
Journal:  Gut       Date:  2013-11-12       Impact factor: 23.059

View more
  2 in total

1.  Chronic High-Fat Diet Induces Early Barrett's Esophagus in Mice through Lipidome Remodeling.

Authors:  Jeffrey Molendijk; Thi-My-Tam Nguyen; Ian Brown; Ahmed Mohamed; Yenkai Lim; Johanna Barclay; Mark P Hodson; Thomas P Hennessy; Lutz Krause; Mark Morrison; Michelle M Hill
Journal:  Biomolecules       Date:  2020-05-16

2.  Impact of Deoxycholic Acid on Oesophageal Adenocarcinoma Invasion: Effect on Matrix Metalloproteinases.

Authors:  Fran Quilty; Anne-Marie Byrne; John Aird; Sheeren El Mashad; Adolfo Parra-Blanco; Aideen Long; John F Gilmer; Carlos Medina
Journal:  Int J Mol Sci       Date:  2020-10-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.